Accurate lists of current clinical trials are maintained by a number of national authorities. The information is intended for people looking for trials to participate in. However, it may also be useful for those interested in the research that is currently underway.
The databases listed below provide information on current clinical trials (Project title, Description of project, Location, Start date, End date). It is worth searching more than one of these databases as none appear comprehensive:
We have an ongoing list of updates to trials and new trials here:
-
MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis (0991-037)6 February 2004
Condition: Aspergillosis
Interventions: Drug: MK0991, caspofungin acetate; Drug: Comparator: amphotericin B; Drug: Comparator: lipid formulation of amphotericin B and/or azole
Sponsor: Merck Sharp & Dohme Corp.
Completed -
Voriconazole With or Without Interferon Gamma in Treating Patients With Aspergillosis or Other Fungal Infections7 May 2003
Conditions: Infection; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: recombinant interferon gamma; Drug: voriconazole
Sponsor: National Cancer Institute (NCI)
Completed -
Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis10 December 2002
Conditions: Acquired Immunodeficiency Syndrome; Aspergillosis; HIV Infections; Immunologic Deficiency Syndromes; Neutropenia
Interventions: Drug: Voriconazole; Drug: Amphotericin B
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Completed -
Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis24 October 2002
Condition: Aspergillosis
Interventions: Drug: Micafungin; Drug: Liposomal Amphotericin B
Sponsor: Astellas Pharma Inc
Terminated -
A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).17 May 2002
Condition: Aspergillosis
Intervention: Drug: Anidulafungin, VER002
Sponsors: Pfizer; Vicuron Pharmaceuticals
Completed -
Study of FK463 for the Treatment of Invasive Aspergillosis9 May 2002
Condition: Aspergillosis
Intervention: Drug: FK463
Sponsor: Astellas Pharma Inc
Completed